Brief: NeNewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib plus Ezetimibe in Patients with HeFH and/or ASCVD or ASCVD Risk Factors
08/07/2024 13:10
July 8 (Reuters) - NewAmsterdam Pharma Company NV
KH6.F :
* NEWAMSTERDAM PHARMA COMPLETES ENROLLMENT IN PIVOTAL PHASE
3
TANDEM CLINICAL TRIAL EVALUATING FIXED-DOSE COMBINATION OF
OBICETRAPIB PLUS EZETIMIBE IN PATIENTS WITH HEFH AND/OR ASCVD OR
ASCVD RISK FACTORS
Source text for Eikon: ID:nGNX38yJNr
Further company coverage: KH6.F
((Reuters.Briefs@thomsonreuters.com;))
Recent news on NewAmsterdam Pharma
See all newsBrief: Menarini Group & Newamsterdam Pharma Receive European Commission Approval For Ubeslo And Evlarco
Amgen falls after Novartis trial setback, BMO downgrade
Brief: Newamsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Newamsterdam Pharma Company N.V. - Announces Positive CHMP Opinion For Obicetrapib And Obicetrapib/Ezetimibe
Brief: NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)